Lincoln Pharma shares gain nearly 5% on oral spray launch

Shares of Lincoln Pharmaceuticals surged nearly 5 per cent today after the company launched Ondansetron oral spray, used for treatment of nausea and vomiting caused by surgery or cancer drugs, in India.
The stock gained 4.71 per cent to Rs 247.85 on BSE.
At NSE, shares of the company jumped 4.64 per cent to Rs 247.80.
Ondansetron was earlier available as tablet, syrup and injectable in India, Lincoln Pharma said in a filing to BSE yesterday.
The company has "done bio-equivalent study for Ondansetron oral spray and has got the Drug Controller General of India (DCGI) permission," it added.
The product has been launched in the Indian market in two strengths, Lincoln Pharma said.

Ondansetron is used to prevent nausea and vomiting caused by cancer chemotherapy, radiation therapy, and surgery.